Zobrazeno 1 - 10
of 752
pro vyhledávání: '"Essential thrombocythaemia"'
Autor:
Michael R. Grunwald, Ellen K. Ritchie, Elisa Rumi, Albert Assad, J. E. Hamer‐Maansson, Jingbo Yu, Tricia Kalafut, Evan Braunstein, Francesco Passamonti
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 778-783 (2024)
Abstract Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory to hydroxyurea. Ruxolitinib has been shown to improve symptoms in patients with
Externí odkaz:
https://doaj.org/article/6bdb75eeb74c4a4e830c97716856dfc8
Autor:
Lai Yee Orbell, Nouf Abutheraa, Andrew S Duncombe, Mary Frances McMullin, Ruben Mesa, Charlene M McShane, Glen James, Lesley A Anderson
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 1071-1080 (2023)
Abstract Alleviating symptom burden in patients with myeloproliferative neoplasms (MPNs) is imperative to achieving optimal management. Research remains to elucidate the relationship between the JAK2V617F (Janus kinase 2) mutation present in many MPN
Externí odkaz:
https://doaj.org/article/028c2022644a45cea8818fdbea71bab2
Publikováno v:
European Journal of Case Reports in Internal Medicine (2024)
Anagrelide is a medication primarily used to manage thrombocytosis, an abnormal increase in platelet levels in the blood. It is often prescribed for patients with myeloproliferative disorders, such as essential thrombocythaemia (ET). Given the height
Externí odkaz:
https://doaj.org/article/fb172816d67741c891a7982ae9d5ad22
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 902-908 (2022)
Objective Calreticulin (CALR) mutations have been identified as driver mutations in a quarter of patients with essential thrombocythaemia (ET) and primary myelofibrosis (PMF), which are subgroups of myeloproliferative neoplasms (MPNs). A 52-bp deleti
Externí odkaz:
https://doaj.org/article/4853e2cb2c38476abcfb36a24611a98e
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1305-1309 (2022)
Abstract Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in M
Externí odkaz:
https://doaj.org/article/e227082c1857411d91eeb12e2888d670
Autor:
Lewis Carpenter, Patrick Rockenschaub, Grace B. Hatton, Sofia D'Abrantes, Edward Sims, Nicholas Scott‐Ram, Aurélie Ducès, Gabrielle Emanuel, Adam J. Mead, Mark W. Drummond, Nadezda Lipunova
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 785-793 (2022)
Abstract There is sparse evidence of how well haematological targets are met in practice for essential thrombocythemia (ET) and polycythaemia vera (PV) patients. Patient data was collected between 2008 and 2020 from two UK NHS Trusts for ET and PV pa
Externí odkaz:
https://doaj.org/article/72d7bd04c7e94405b6a5c3220078eb2a
Autor:
Jumoke Okikiolu, Claire Woodley, Llywelyn Cadman-Davies, Jennifer O'Sullivan, Deepti Radia, Natalia Curto Garcia, Patrick Harrington, Shahram Kordasti, Susan Asirvatham, Priya Sriskandarajah, Jamie Saunders, Chandan Saha, Irene Sanchez, Hugues deLavallade, Donal P McLornan, Claire N Harrison
Publikováno v:
Leukemia Research Reports, Vol 19, Iss , Pp 100360- (2023)
Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa
Externí odkaz:
https://doaj.org/article/c09dc41d2ca24fb0853b44f1560e6c69
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-18 (2021)
Abstract The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. Despite distinct clinica
Externí odkaz:
https://doaj.org/article/e74e2a46bd8c46faaca97b7443183326
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1544-1557 (2021)
Background: There is a paucity of data on ethnic disparities in patients with the classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs): polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF)
Externí odkaz:
https://doaj.org/article/dfe9b776eed0423b92b2f0cf344e2c08
Autor:
Nicola Padzik, Małgorzata Szewczuk
Publikováno v:
Roczniki Naukowe Polskiego Towarzystwa Zootechnicznego, Vol 17, Iss 1, Pp 13-21 (2021)
A potential cause of essential thrombocythaemia can be seen as the V617F point mutation within Janus kinase 2. This mutation occurs in 60-70% of patients with this disease and is located in the domain acting as an inhibitor. It increases the enzymati
Externí odkaz:
https://doaj.org/article/9e1699cfd2e84ec78f01867596a1f248